Sutro Biopharma Inc STRO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $3.48
- Day Range
- $3.32–3.42
- 52-Week Range
- $2.01–6.12
- Bid/Ask
- $3.38 / $3.39
- Market Cap
- $260.76 Mil
- Volume/Avg
- 136,368 / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.36
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 324
- Website
- https://www.sutrobio.com
Comparables
Valuation
|
Metric
|
STRO
|
MRSN
|
INBX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.41 | 9.42 | 37.44 |
Price/Sales | 1.36 | 9.07 | 900.19 |
Price/Cash Flow | — | — | — |
Price/Earnings
STRO
MRSN
INBX
Financial Strength
|
Metric
|
STRO
|
MRSN
|
INBX
|
|---|---|---|---|
Quick Ratio | 4.39 | 3.29 | 4.95 |
Current Ratio | 4.50 | 3.36 | 5.25 |
Interest Coverage | −3.34 | −44.11 | −6.90 |
Quick Ratio
STRO
MRSN
INBX
Profitability
|
Metric
|
STRO
|
MRSN
|
INBX
|
|---|---|---|---|
Return on Assets (Normalized) | −22.26% | −49.57% | −77.08% |
Return on Equity (Normalized) | −57.95% | −211.52% | −500.57% |
Return on Invested Capital (Normalized) | −42.52% | −146.81% | −81.45% |
Return on Assets
STRO
MRSN
INBX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fxdqsnbdq | Wsdlk | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gjndlcx | Lqfsfh | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mxrlkbxl | Jnctwvw | $99.5 Bil | |
MRNA
| Moderna Inc | Pzkgqgql | Kmyl | $38.8 Bil | |
ARGX
| argenx SE ADR | Fgrhzjhq | Fztd | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Ljwprsjb | Kxxr | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vtkzvmyp | Ffyncn | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xkdvdlnh | Qpwgffn | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bhzcjkjt | Rhdxkp | $12.5 Bil | |
INCY
| Incyte Corp | Jnsqxgl | Psxlyp | $11.6 Bil |